Physical Dependence

16 May

As with many other drugs, the continuous application of opioids over of longer periods of time produces physical (and psychological) dependence. Stopping the drug abruptly causes a stereotypical withdrawal syndrome that includes restlessness, mydriasis, gooseflesh, runny nose, diarrhea, shaking chills, and drug seeking (Heit 2003). The rate of onset of these symptoms depends upon the rate at which the opioid is eliminated.  Administration of an opioid an- tagonist can cause an immediate  “precipitated”  withdrawal. The symptoms of withdrawal are terminated  rapidly by administering  opioid agonists. Phys- ical dependence  must  be distinguished  from  psychological dependence  or addiction, which includes the dimension of compulsive drug-seeking behavior (Enck 1991). However, some investigations  suggest that addiction  resulting from appropriate medical treatment  is a very unusual event (Porter and Jick 1980).

Acknowledgements   We thank Dr. Stefan Schulz for critical reading of the manuscript.

References

Adriaensen H, Vissers K, Noorduin H, Meert T (2003) Opioid tolerance and dependence:

an inevitable consequence of chronic treatment? Acta Anaesthesiol Belg 54:37–47

Akins PT, McCleskey EW (1993) Characterization of potassium currents in adult rat sensory neurons and modulation by opioids and cyclic AMP. Neuroscience 56:759–769

Antonijevic I, Mousa SA, Schäfer M, Stein C (1995) Perineurial defect and peripheral opioid analgesia in inflammation. J Neurosci 15:165–172

Apfel CC, Korttila K, Abdalla M, Kerger H, Turan A, Vedder I, Zernak C, Danner K, Jokela R, Posock SJ, Trenkler S, Kredel M, Biedler A, Sessler DI, Roewer N (2004) A factorial trial of six interventions  for the prevention  of postoperative  neusea and vomiting. N Engl J Med 350:2441–2451

Arandia HY, Patil VU (1987) Glottic closure following large doses of fentanyl. Anesthesiology

66:574–575

Attali B, Gouarderes C, Mazarguil H, Audigier Y, Cros J (1982) Evidence for multiple “Kappa” binding  sites by use of opioid  peptides  in the guinea-pig  lumbo-sacral  spinal cord. Neuropeptides 3:53–64

Ballantyne JC, Loach AB, Carr DB (1989) The incidence of pruritus after epidural morphine.

Anaesthesia 44:863

Barke KE, Hough LB (1993) Opiates, mast cells and histamine release. Life Sci 53:1391–1399

Becker LD, Paulson BA, Miller RD, Severinghaus JW, Eger EI 2nd (1976) Biphasic respiratory depression after fentanyldroperidol or fentanyl alone used to supplement nitrous oxide anesthesia. Anesthesiology 44:291–296

Belcheva MM, Bohn LM, Ho MT, Johnson FE, Yanai J, Barron S, Coscia CJ (1998) Brain opioid receptor adaptation  and expression after prenatal  exposure to buprenorphine. Brain Res Dev Brain Res 111:35–42

Belcheva MM, Clark AL, Haas PD, Serna JS, Hahn JW, Kiss A, Coscia CJ (2005) Mu and

kappa opioid receptors activate ERK/MAPK via different protein kinase C isoforms and secondary messengers in astrocytes. J Biol Chem 280:27662–27669

Benthuysen JL, Smith NT, Sanford TJ, Head N, Dec-Silver H (1986) Physiology of alfentanil- induced rigidity. Anesthesiology 64:440–446

Binder W, Machelska H, Mousa S, Schmitt T, Riviere PJ, Junien JL, Stein C, Schäfer M  (2001) Analgesic and  antiinflammatory effects of two novel kappa-opioid  peptides. Anesthesiology 94:1034–1044

Bohn LM, Gainetdinov RR, Lin FT, Lefkowitz RJ, Caron MG (2000) Mu-opioid receptor desensitization by beta-arrestin-2  determines morphine tolerance but not dependence. Nature 408:720–723

Bohn LM, Lefkowitz RJ, Caron MG (2002) Differential mechanisms of morphine antinoci-

ceptive tolerance revealed in (beta)arrestin-2 knock-out mice. J Neurosci 22:10494–10500

Bohn LM, Dykstra LA, Lefkowitz RJ, Caron MG, Barak LS (2004) Relative opioid efficacy is determined  by the complements  of the G protein-coupled receptor  desensitization machinery. Mol Pharmacol 66:106–112

Bowdle TA (1998) Adverse effects of opioid agonists and agonist-antagonists in anaesthesia.

Drug Saf 19:173–189

Bowdle TA, Rooke GA (1994) Postoperative myoclonus and rigidity after anesthesia with opioids. Anesth Analg 78:783–786

Caldwell JR, Hale ME, Boyd RE, Hague JM, Iwan T, Shi M, Lacouture PG (1999) Treatment of osteoarthritis pain with controlled release oxycodone or fixed combination oxycodone plus acetaminophen  added  to nonsteroidal  antiinflammatory drugs: a double blind, randomized, multicenter, placebo controlled trial. J Rheumatol 26:862–869

Cao Z, Liu L, VanWinkle DM (2003) Activation of delta- and kappa-opioid  receptors  by opioid peptides protects cardiomyocytes via KATP channels. Am J Physiol Heart Circ Physiol 285:1032–1039

Cao Z, Liu L, Van Winkle DM (2005) Met5-enkephalin-induced cardioprotection occurs via transactivation  of EGFR and activation of PI3 K. Am J Physiol Heart Circ Physiol

288:1955–1964

Capeyrou R, Riond J, Corbani M, Lepage JF, Bertin B, Emorine LJ (1997) Agonist-induced signaling and trafficking of the mu-opioid receptor: role of serine and threonine residues in the third cytoplasmic loop and C-terminal domain. FEBS Lett 415:200–205

Chan JS, Chiu TT, Wong YH (1995) Activation of type II adenylyl cyclase by the cloned mu-opioid receptor: coupling to multiple G proteins. J Neurochem 65:2682–2689

Chaney MA (1995) Side effects of intrathecal and epidural opioids. Can J Anaesth 42:891–903

Chen JJ, Dymshitz J, Vasko MR (1997) Regulation of opioid receptors in rat sensory neurons in culture. Mol Pharmacol 51:666–673

Chou DT, Wang SC (1975) Studies on the localization of central cough mechanism; site of

action of antitussive drugs. J Pharmacol Exp Ther 194:499–505

Chung KF, Chang AB (2002) Therapy  for cough: active agents. Pulm Pharmacol  Ther

15:335–338

Comb M, Seeburg PH, Adelman J, Eiden L, Herbert E (1982) Primary structure of the human

Met- and Leu-enkephalin precursor and its mRNA. Nature 295:663–666

Costall B, Fortune DH, Naylor RJ (1978) Involvement of mesolimbic and extrapyramidal nuclei in the motor depressant action of narcotic drugs. J Pharm Pharmacol 30:566–572

Cowan A, Lewis JW, Macfarlane IR (1977) Agonist and antagonist properties of buprenor- phine, a new antinociceptive agent. Br J Pharmacol 60:537–545

De Luca A, Coupar IM (1996) Insights into action in the intestinal tract. Pharmacol Ther

69:103–115

Decaillot FM, Befort K, Filliol D, Yue S, Walker P, Kieffer BL (2003) Opioid receptor random mutagenesis reveals a mechanism for G protein-coupled receptor activation. Nat Struct Biol 10:629–636

Dershwitz M, Walsh JL, Morishige RJ, Connors PM, Rubsamen RM, Shafer SL, Rosow CE

(2000) Pharmacokinetics  and pharmacodynamics of inhaled versus intravenous  mor- phine in healthy volunteers. Anesthesiology 93:619–628

Eilers H, Schumacher MA (2004) Opioid-induced respiratory depression: are 5-HT4a recep- tor agonists the cure? Mol Interv 4:197–199

Eisenach JC, Carpenter R, Curry R (2003) Analgesia from a peripherally active kappa-opioid receptor agonist in patients with chronic pancreatitis. Pain 101:89–95

Eisinger DA, Ammer H, Schulz R (2002) Chronic morphine  treatment  inhibits opioid re- ceptor desensitization and internalization.  J Neurosci 22:10192–10200

Elliott K, Kest B, Man A, Kao B, Inturrisi CE (1995) N-methyl-D-aspartate (NMDA) receptors, mu and kappa opioid tolerance, and perspectives on new analgesic drug development. Neuropsychopharmacology 13:347–356

Enck RE (1991) Understanding  tolerance, physical dependence and addiction in the use of opioid analgesics. Am J Hosp Palliat Care 8:9–11

Evans CJ, Keith DE Jr, Morrison H, Magendzo K, Edwards RH (1992) Cloning of a delta opioid receptor by functional expression. Science 258:1952–1955

Forrest WH Jr, Bellville JW (1964) The effect of sleep plus morphine  on the respiratory response to carbon dioxide. Anesthesiology 25:137–141

Furst S, Riba P, Friedmann  T, Timar J, Al-Khrasani M, Obara I, Makuch W, Spetea M, Schutz J, Przewlocki R, Przewlocka B, Schmidhammer  H (2005) Peripheral versus cen- tral antinociceptive actions of 6-amino acid-substituted derivatives of 14-O-methyloxy- morphone in acute and inflammatory pain in the rat. J Pharmacol Exp Ther 312:609–618

Gavériaux-Ruff C, Kieffer BL (2002) Opioid receptor genes inactivated in mice: the high- lights. Neuropeptides 36:62–71

Gavériaux-Ruff C, Filliol D, Simonin F, Matthes HW, Kieffer BL (2001) Immunosuppression by delta-opioid antagonist naltrindole: delta- and triple mu/delta/kappa-opioid receptor knockout mice reveal a nonopioid activity. J Pharmacol Exp Ther 298:1193–1198

Gavériaux-Ruff C, Kieffer BL (1999b) Opioid receptors: gene structure  and function. In: Stein C (ed) Opioids in pain control. Cambridge University Press, Cambridge, pp 1–20

Gold MS, Levine JD (1996) DAMGO inhibits  prostaglandin  E2-induced potentiation of a TTX-resistant Na+ current in rat sensory neurons in vitro. Neurosci Lett 212:83–86

Gong L, Middleton RK (1992) Sublingual administration of opioids. Ann Pharmacother

26:1525–1527

Gouarderes C, Tellez S, Tafani JA, Zajac JM (1993) Quantitative autoradiographic mapping of delta-opioid receptors in the rat central nervous system using [125I][D.Ala2]deltorphin- I. Synapse 13:231–240

Greaves MW, Wall PD (1996) Pathophysiology of itching. Lancet 348:938–940

Hanna MH, Elliott KM, Fung M (2005) Randomized, double-blind  study of the analgesic efficacy of morphine-6-glucuronide versus morphine  sulfate for postoperative  pain in maijor surgery. Anesthesiology 102:815–821

Hassan AH, Ableitner A, Stein C, Herz A (1993) Inflammation  of the rat paw enhances axonal transport of opioid receptors in the sciatic nerve and increases their density in the inflamed tissue. Neuroscience 55:185–195

Heinricher M, Morgan M (1999) Supraspinal mechanisms of opioid analgesia. In: Stein C

(ed) Opioids in pain control: basic and clinical aspects. Cambridge University Press, Cambridge, pp 46–69

Heit HA (2003) Addiction, physical dependence, and tolerance: precise definitions to help clinicians evaluate and treat chronic pain patients.  J Pain Palliat Care Pharmacother

17:15–29

Herlitze S, Garcia DE, Mackie K, Hille B, Scheuer T, Catterall WA (1996) Modulation of Ca2+

channels by G-protein beta gamma subunits. Nature 380:258–262

Höllt V (1993) Regulation of opioid peptide gene expression. In: Herz A (ed) Opioids I. (Handbook of experimental pharmacology) Springer Verlag, New York, pp 307–346

Holzner P (2004) Opioids and opioid receptors in the enteric nervous system: from a problem in opioid  analgesia to a possible new prokinetic  therapy  in humans.  Neurosci Lett

361:192–195

Horvath  G (2000) Endomorphin-1 and  endomorphin-2:  pharmacology  of the selective endogenous mu-opioid receptor agonists. Pharmacol Ther 88:437–463

Hug CC Jr, Murphy MR (1979) Fentanyl disposition in cerebrospinal fluid and plasma and its relationship to ventilatory depression in the dog. Anesthesiology 50:342–349

Hughes J, Smith TW, Kosterlitz HW, Fothergill LA, Morgan BA, Morris HR (1975) Identifi- cation of two related pentapeptides  from the brain with potent opiate agonist activity. Nature 258:577–580

Hulme  EC, Lu ZL, Ward  SD, Allman K, Curtis  CA (1999) The conformational  switch

in 7-transmembrane receptors:  the muscarinic  receptor  paradigm.  Eur J Pharmacol

375:247–260

Ignatova  EG, Belcheva MM, Bohn LM, Neumann  MC, Coscia CJ (1999) Requirement of receptor  internalization   for  opioid  stimulation  of mitogen-activated  protein  ki- nase: biochemical and immunofluorescence confocal microscopic evidence. J Neurosci

19:56–63

Ingram  SL, Williams  JT (1994) Opioid  inhibition  of Ih  via adenylyl cyclase. Neuron

13:179–186

Kakidani H, Furutani Y, Takahashi H, Noda M, Morimoto Y, Hirose T, Asai M, Inayama S, Nakanishi S, Numa S (1982) Cloning and sequence analysis of cDNA for porcine beta- neo-endorphin/dynorphin precursor. Nature 298:245–249

Kalso E, Smith L, McQuay HJ, Andrew Moore R (2002) No pain, no gain: clinical excellence and scientific rigour-lessons learned from IA morphine. Pain 98:269–275

Karnik SS, Gogonea C, Patil S, Saad Y, Takezako T (2003) Activation of G-protein-coupled receptors: a common molecular mechanism. Trends Endocrinol Metab 14:431–437

Khodorova  A, Navarro  B, Jouaville LS, Murphy  JE, Rice FL, Mazurkiewicz JE, Long- Woodward D, Stoffel M, Strichartz GR, Yukhananov R, Davar G (2003) Endothelin-B receptor activation triggers an endogenous analgesic cascade at sites of peripheral in- jury. Nat Med 9:1055–1061

Kieffer B, Befort K, Gaveriaux-Ruff C, Hirth C (1992) The δ-opioid receptor: isolation of

a cDNA by expression cloning and pharmacological characterization. Proc Natl Acad Sci

U S A 90:12048–12052

Kieffer BL (1999a) Opioids: first lessons from knockout mice. Trends Pharmacol Sci 20:19–26

Kieffer BL, Gaveriaux-Ruff C (2002) Exploring the opioid system by gene knockout. Prog

Neurobiol 66:285–306

Kilpatrick GJ, Smith TW (2005) Morphine-6-glucuronide: actions and mechanisms.  Med

Res Rev 25:521–544

Kissin I, Vinik HR, Castillo R, Bradley EL Jr (1990) Alfentanil potentiates  midazolam- induced unconsciousness in subanalgesic doses. Anesth Analg 71:65–69

Kjellberg F, Tramer MR (2001) Pharmacological control of opioid-induced pruritus: a quan- titative systematic review of randomized trials. Eur J Anaesthesiol 18:346–357

Klco JM, Wiegand CB, Narzinski K, Baranski TJ (2005) Essential role for the second extra- cellular loop in C5a receptor activation. Nat Struct Mol Biol 12:320–326

Koch T, Schulz S, Schroder H, Wolf R, Raulf E, Hollt V (1998) Carboxyl-terminal splicing of the rat mu opioid receptor modulates agonist-mediated  internalization  and receptor resensitization. J Biol Chem 273:13652–13657

Koch T, Schulz S, Pfeiffer M, Klutzny M, Schroder H, Kahl E, Hollt V (2001) C-terminal splice

variants of the mouse mu-opioid  receptor differ in morphine-induced internalization and receptor resensitization. J Biol Chem 276:31408–31414

Koch T, Widera A, Bartzsch K, Schulz S, Brandenburg LO, Wundrack N, Beyer A, Grecksch G, Hollt V (2005) Receptor endocytosis counteracts  the development of opioid tolerance. Mol Pharmacol 67:280–287

Kolesnikov YA, Chereshnev I, Pasternak  GW (2000) Analgesic synergy between topical

lidocaine and topical opioids. J Pharmacol Exp Ther 295:546–551

Kondo I, Marvizon JC, Song B, Salgado F, Codeluppi S, Hua XY, Yaksh TL (2005) Inhibition by spinal mu- and delta-opioid agonists of afferent-evoked substance P release. J Neurosci

25:3651–3660

Krajnik M, Zylicz Z, Finlay I, Luczak J, van Sorge AA (1999) Potential uses of topical opioids in palliative care—report of 6 cases. Pain 80:121–125

Kraus J, Borner C, Giannini E, Hickfang K, Braun H, Mayer P, Hoehe MR, Ambrosch A, Konig W, Ho¨llt V (2001) Regulation of mu-opioid receptor gene transcription by interleukin-

4 and influence of an allelic variation within a STAT6 transcription factor binding site. J Biol Chem 276:43901–43908

Kumar V, Guo D, Cassel JA, Daubert JD, Dehaven RN, Dehaven-Hudkins DL, Gauntner EK,

Gottshall SL, Greiner SL, Koblish M, Little PJ, Mansson E, Maycock AL (2005) Synthesis and evaluation of novel peripherally restricted kappa-opioid  receptor agonists. Bioorg Med Chem Lett 15:1091–1095

Ladd LA, Kam PC, Williams DB, Wright AW, Smith MT, Mather  LE (2005) Ventilatory

responses of healthy subjects to intravenous combinations of morphine and oxycodone under imposed hypercapnic and hypoxaemic conditions. Br J Clin Pharmacol 59:524–535

Laduron PM, Castel MN (1990) Axonal transport of receptors. A major criterion for presy- naptic localization. Ann N Y Acad Sci 604:462–469

Lal J, Krutak-Krol H, Domino EF (1986) Comparative antitussive effects of dextrorphan,

dextromethorphan and phencyclidine. Arzneimittelforschung 36:1075–1078

Law PY, Wong YH, Loh HH (2000) Molecular mechanisms and regulation of opioid receptor signaling. Annu Rev Pharmacol Toxicol 40:389–430

Lee AY (1992) Stereospecific antiarrhythmic effects of naloxone  against  myocardial  is- chaemia and reperfusion in the dog. Br J Pharmacol 107:1057–1060

Liang CS, Imai N, Stone CK, Woolf PD, Kawashima S, Tuttle RR (1987) The role of endoge- nous opioids in congestive heart failure: effects of nalmefene on systemic and regional hemodynamics in dogs. Circulation 75:443–451

Likar R, Sch¨afer M, Paulak F, Sittl R, Pipam W, Schalk H, Geissler D, Bernatzky G (1997) Intraarticular morphine  analgesia in chronic pain patients with osteoarthritis.  Anesth Analg 84:1313–1317

Likar R, Sittl R, Gragger K, Pipam W, Blatnig H, Breschan C, Schalk HV, Stein C, Schäfer M (1998) Peripheral morphine analgesia in dental surgery. Pain 76:145–150

Long TD, Cathers TA, Twillman R, O’Donnell T, Garrigues N, Jones T (2001) Morphine- Infused silver sulfadiazine (MISS) cream for burn analgesia: a pilot study. J Burn Care Rehabil 22:118–123

Lord JA, Waterfield  AA, Hughes J, Kosterlitz HW (1977) Endogenous  opioid  peptides:

multiple agonists and receptors. Nature 267:495–499

Lotsch J (2005a) Opioid metabolites. J Pain Symptom Manage 29:S10–24

Lotsch J (2005b) Pharmacokinetic-pharmacodynamic modeling of opioids. J Pain Symptom

Manage 29:S90–103

Machelska H, Cabot PJ, Mousa SA, Zhang Q, Stein C (1998) Pain control in inflammation governed by selectins. Nat Med 4:1425–1428

Machelska H, Mousa SA, Brack A, Schopohl JK, Rittner HL, Schäfer M, Stein C (2002) Opioid control of inflammatory pain regulated by intercellular adhesion molecule-1. J Neurosci

22:5588–5596

Maekawa K, Minami M, Masuda T, Satoh M (1996) Expression of mu- and kappa-, but not delta-, opioid receptor mRNAs is enhanced in the spinal dorsal horn of the arthritic rats. Pain 64:365–371

Mansour A, Taylor LP, Fine JL, Thompson RC, Hoversten MT, Mosberg HI, Watson SJ, AkilH

(1997) Key residues defining the mu-opioid  receptor  binding  pocket: a site-directed mutagenesis study. J Neurochem 68:344–353

Manzke T, Guenther U, Ponimaskin EG, Haller M, Dutschmann M, Schwarzacher S, Richter DW (2003) 5-HT4(a) receptors  avert opioid-induced  breathing  depression  without loss of analgesia. Science 301:226–229

Mao J (1999) NMDA and opioid receptors: their interactions  in antinociception,  tolerance and neuroplasticity. Brain Res Brain Res Rev 30:289–304

Martin  WR, Eades CG, Thompson  JA, Huppler  RE, Gilbert  PE (1976) The effects of morphine-  and nalorphine-like  drugs in the nondependent and morphine-dependent chronic spinal dog. J Pharmacol Exp Ther 197:517–532

Massotte D, Kieffer BL (2005) The second extracellular loop: a damper for G protein-coupled receptors? Nat Struct Mol Biol 12:287–288

Mattia A, Vanderah T, Mosbert HI, Porreca F (1991) Lack of antinociceptive cross-tolerance between [D-Pen2, D-Pen5]enkephalin  and [D-Ala2]deltorphin II in mice: evidence for delta receptor subtypes. J Pharmacol Exp Ther 258:583–587

Meng F, Xie GX, Thompson RC, Mansour A, Goldstein A, Watson SJ, Akil H (1993) Cloning and pharmacological characterization of a rat kappa opioid receptor. Proc Natl Acad Sci U S A 90:9954–9958

Moulin DE, Iezzi A, Amireh R, Sharpe WK, Boyd D, Merskey H (1996) Randomised trial of

oral morphine for chronic non-cancer pain. Lancet 347:143–147

Mousa SA, Machelska H, Schäfer M, Stein C (2000) Co-expression of beta-endorphin with adhesion molecules in a model of inflammatory pain. J Neuroimmunol 108:160–170

Nakanishi S, Inoue A, Kita T, Nakamura M, Chang AC, Cohen SN, Numa S (1979) Nucleotide sequence of cloned cDNA for bovine corticotropin-beta-lipotropin precursor.  Nature

278:423–427

Narita  M, Tseng LF (1998) Evidence for the  existence of the  beta-endorphin-sensitive “epsilon-opioid receptor” in the brain: the mechanisms of epsilon-mediated  antinoci- ception. Jpn J Pharmacol 76:233–253

Negus SS, Picker MJ, Dykstra LA (1989) Kappa antagonist properties of buprenorphine in non-tolerant and morphine-tolerant rats. Psychopharmacology (Berl) 98:141–143

Ocana M, Del Pozo E, Barrios M, Baeyens JM (1995) Subgroups among mu-opioid recep- tor agonists distinguished  by ATP-sensitive K+  channel-acting  drugs. Br J Pharmacol

114:1296–1302

Ocana M, Cendan CM, Cobos EJ, Entrena JM, Baeyens JM (2004) Potassium channels and pain: present realities and future opportunities. Eur J Pharmacol 500:203–219

Palczewski K, Kumasaka T, Hori T, Behnke CA, Motoshima H, Fox BA, Le Trong I, Teller DC, Okada T, Stenkamp RE, Yamamoto M, Miyano M (2000) Crystal structure of rhodopsin: a G protein-coupled receptor. Science 289:739–745

Pasternak GW (2004) Multiple opiate receptors: deja vu all over again. Neuropharmacology

47:312–323

Patwardhan AM, Berg KA, Akopain AN, Jeske NA, Gamper N, Clarke WP, Hargreaves KM (2005) Bradykinin-induced  functional competence and trafficking of the delta-opioid receptor in trigeminal nociceptors. J Neurosci 25:8825–8832

Peloso PM, Bellamy N, Bensen W, Thomson GT, Harsanyi Z, Babul N, Darke AC (2000) Double blind  randomized  placebo control  trial of controlled  release codeine in the treatment of osteoarthritis of the hip or knee. J Rheumatol 27:764–771

Pepe S, van den Brink OW, Lakatta EG, Xiao RP (2004) Cross-talk of opioid peptide receptor and beta-adrenergic receptor signalling in the heart. Cardiovasc Res 63:414–422

Pert  CB, Snyder SH (1973) Opiate  receptor:  demonstration in nervous  tissue.  Science

179:1011–1014

Peyman GA, Rahimy MH, Fernandes  ML (1994) Effects of morphine  on corneal sensi- tivity and epithelial wound healing: implications for topical ophthalmic  analgesia. Br J Ophthalmol 78:138–141

Pierce KL, Tohgo A, Ahn S, Field ME, Luttrell LM, Lefkowitz RJ (2001) Epidermal growth factor (EGF) receptor-dependent ERK activation by G protein-coupled receptors: a co- culture  system for identifying intermediates  upstream  and downstream  of heparin- binding EGF shedding. J Biol Chem 276:23155–23160

Pol O, Puig MM (1997) Reversal of tolerance to the antitransit  effects of morphine  during acute intestinal inflammation in mice. Br J Pharmacol 122:1216–1222

Polakiewicz RD, Schieferl SM, Dorner LF, Kansra V, Comb MJ (1998) A mitogen-activated

protein kinase pathway is required for mu-opioid receptor desensitization. J Biol Chem

273:12402–12406

Portenoy RK, Khan E, Layman M, Lapin J, Malkin MG, Foley KM, Thaler HT, Cerbone DJ, Inturrisi CE (1991) Chronic morphine therapy for cancer pain: plasma and cerebrospinal fluid morphine and morphine-6-glucuronide concentrations.  Neurology 41:1457–1461

Porter J, Jick H (1980) Addiction rare in patients treated with narcotics. N Engl J Med 302:123

Price DD, Mayer DJ, Mao J, Caruso  FS (2000) NMDA-receptor antagonists  and  opioid receptor  interactions  as related to analgesia and tolerance.  J Pain Symptom Manage

19:S7–11

Puehler W, Zöllner C, Brack A, Shaqura M, Krause H, Schäfer M, Stein C (2004) Rapid upregulation of μ opioid receptor mRNA in dorsal root ganglia in response to peripheral inflammation  depends on neuronal conduction. Neuroscience 129:473–479

Rittner HL, Brack A, Machelska H, Mousa SA, Bauer M, Schäfer M, Stein C (2001) Opioid peptide-expressing leukocytes: identification, recruitment, and simultaneously increas- ing inhibition of inflammatory pain. Anesthesiology 95:500–508

Roques BP (2000) Novel approaches to targeting neuropeptide systems. Trends Pharmacol

Sci 21:475–483

Rubovitch V, Gafni M, Sarne Y (2003) The mu opioid agonist DAMGO stimulates cAMP production  in SK-N-SH cells through  a PLC-PKC-Ca++ pathway. Brain Res Mol Brain Res 110:261–266

Schmidt H, Schulz S, Klutzny M, Koch T, Handel M, Ho¨llt V (2000) Involvement of mitogen- activated protein kinase in agonist-induced  phosphorylation of the mu-opioid receptor in HEK 293 cells. J Neurochem 74:414–422

Schmidt WK (2001) Alvimopan (ADL 8–2698) is a novel peripheral opioid antagonist. Am

J Surg 182:27–38

Schmitz R (1985) Friedrich Wilhelm Serturner and the discovery of morphine. Pharm Hist

27:61–74

Schug SA, Zech D, Grond S (1992) Adverse effects of systemic opioid analgesics. Drug Saf

7:200–213

Schultz JJ, Hsu AK, Gross GJ (1997) Ischemic preconditioning and morphine-induced car- dioprotection  involve the delta (delta)-opioid receptor in the intact rat heart. J Mol Cell Cardiol 29:2187–2195

Schulz R, Eisinger DA, Wehmeyer A (2004a) Opioid control of MAP kinase cascade. Eur

J Pharmacol 500:487–497

Schulz S, Mayer D, Pfeiffer M, Stumm R, Koch T, Hollt V (2004b) Morphine induces termi- nal micro-opioid  receptor desensitization  by sustained phosphorylation of serine-375. EMBO J 23:3282–3289

Seger R, Krebs EG (1995) The MAPK signaling cascade. FASEB J 9:726–735

Servin F (2003) Remifentanil; from pharmacological properties to clinical practice. Adv Exp

Med Biol 523:245–260

Shaiova L (2005) The management  of opioid-related  sedation.  Curr Pain Headache Rep

9:239–242

Shaqura MA, Zöllner C, Mousa SA, Stein C, Schäfer M (2004) Characterization of mu opioid receptor binding and G protein coupling in rat hypothalamus, spinal cord, and primary afferent neurons during inflammatory pain. J Pharmacol Exp Ther 308:712–718

Short TG, Plummer  JL, Chui PT (1992) Hypnotic  and anaesthetic  interactions  between midazolam, propofol and alfentanil. Br J Anaesth 69:162–167

Sim LJ, Selley DE, Dworkin SI, Childers SR (1996) Effects of chronic morphine administra- tion on mu opioid receptor-stimulated [35 S]GTPgammaS autoradiography in rat brain. J Neurosci 16:2684–2692

Simonin F, Slowe S, Becker JA, Matthes  HW, Filliol D, Chluba J, Kitchen I, Kieffer BL (2001) Analysis of [3 H]bremazocine binding in single and combinatorial opioid receptor knockout mice. Eur J Pharmacol 414:189–195

Slominski A, Wortsman  J, Luger T, Paus R, Solomon S (2000) Corticotropin  releasing hormone  and proopiomelanocortin involvement in the cutaneous  response to stress. Physiol Rev 80:979–1020

Smith FL, Javed RR, Elzey MJ, Dewey WL (2003) The expression of a high level of morphine antinociceptive tolerance in mice involves both PKC and PKA. Brain Res 985:78–88

Stein A, Yassouridis A, Szopko C, Helmke K, Stein C (1999) Intraarticular morphine versus dexamethasone in chronic arthritis. Pain 83:525–532

Stein C, Millan MJ, Shippenberg TS, Peter K, Herz A (1989) Peripheral opioid receptors

mediating antinociception  in inflammation.  Evidence for involvement of mu, delta and kappa receptors. J Pharmacol Exp Ther 248:1269–1275

Stein C, Hassan AH, Lehrberger K, Giefing J, Yassouridis A (1993) Local analgesic effect of endogenous opioid peptides. Lancet 342:321–324

Stein C, Pfluger M, Yassouridis A, Hoelzl J, Lehrberger K, Welte C, Hassan AH (1996) No tolerance to peripheral morphine analgesia in presence of opioid expression in inflamed synovia. J Clin Invest 98:793–799

Stein C, Schäfer M, Machelska H (2003) Attacking pain at its source: new perspectives on opioids. Nat Med 9:1003–1008

Sternini C, Spann M, Anton B, Keith DE Jr, Bunnett NW, von Zastrow M, Evans C, Brecha NC (1996) Agonist-selective endocytosis of mu opioid receptor by neurons in vivo. Proc Natl Acad Sci U S A 93:9241–9246

Stretton D, Miura M, Belvisi MG, Barnes PJ (1992) Calcium-activated potassium channels

mediate prejunctional inhibition of peripheral sensory nerves. Proc Natl Acad Sci U S A

89:1325–1329

Surratt CK, Johnson PS, Moriwaki A, Seidleck BK, Blaschak CJ, Wang JB, Uhl GR (1994) -mu opiate receptor. Charged transmembrane domain amino acids are critical for agonist recognition and intrinsic activity. J Biol Chem 269:20548–20553

Taguchi A, Sharma N, Saleem RM, Sessler DI, Carpenter RL, Seyedsadr M, Kurz A (2001) Selective postoperative  inhibition  of gastrointestinal  opioid receptors.  N Engl J Med

345:935–940

Tegeder I, Meier S, Burian M, Schmidt H, Geisslinger G, Lotsch J (2003) Peripheral opioid analgesia in experimental human pain models. Brain 126:1092–1102

Townsend Dt, Portoghese PS, Brown DR (2004) Characterization  of specific opioid bind- ing sites in neural membranes  from the myenteric plexus of porcine small intestine. J Pharmacol Exp Ther 308:385–393

Twillman RK, Long TD, Cathers TA, Mueller DW (1999) Treatment  of painful skin ulcers with topical opioids. J Pain Symptom Manage 17:288–292

von Zastrow M (2004) A cell biologist’s perspective on physiological adaptation  to opiate drugs. Neuropharmacology 47 Suppl 1:286–292

Wang HL (2000) A cluster of Ser/Thr residues at the C-terminus of mu-opioid receptor is required for G protein-coupled receptor kinase 2-mediated desensitization. Neurophar- macology 39:353–363

Wang JB, Imai Y, Eppler CM, Gregor P, Spivak CE, Uhl GR (1993) mu opiate receptor: cDNA

cloning and expression. Proc Natl Acad Sci U S A 90:10230–10234

Wang SC, Glaviano VV (1954) Locus of emetic action of morphine and hydergine in dogs.

J Pharmacol Exp Ther 111:329–334

Watson CP, Babul N (1998) Efficacy of oxycodone in neuropathic  pain: a randomized  trial in postherpetic neuralgia. Neurology 50:1837–1841

Weil JV, McCullough RE, Kline JS, Sodal IE (1975) Diminished  ventilatory  response  to hypoxia and hypercapnia after morphine in normal man. N Engl J Med 292:1103–1106

Weinberg DS, Inturrisi  CE, Reidenberg B, Moulin DE, Nip TJ, Wallenstein S, Houde RW, Foley KM (1988) Sublingual absorption  of selected opioid analgesics. Clin Pharmacol Ther 44:335–342

Weinger MB, Smith NT, Blasco TA, Koob GF (1991) Brain sites mediating opiate-induced

muscle rigidity in the rat: methylnaloxonium  mapping study. Brain Res 544:181–190

Whistler JL, Enquist J, Marley A, Fong J, Gladher F, Tsuruda P, Murray SR, von Zastrow M (2002) Modulation  of postendocytic  sorting  of G protein-coupled receptors.  Science

297:615–620

Whiteside GT, Harrison JE, Pearson MS, Chen Z, Fundytus ME, Rotshteyn Y, Turchin PI, Pomonis JD, Mark L, Walker K, Brogle KC (2004) DiPOA ([8-(3,3-diphenyl-propyl)-4- oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-3-yl]-acetic acid), a novel, systemically available, and peripherally restricted Mu opioid agonist with antihyperalgesic activity. II. In vivo pharmacological characterization  in the rat. J Pharmacol Exp Ther 310:793–799

Zacny JP (2005) Differential effects of morphine  and codeine on pupil size: dosing issues.

Anesth Analg 100:598

Zadina JE, Hackler L, Ge LJ, Kastin AJ (1997) A potent and selective endogenous agonist for the mu-opiate receptor. Nature 386:499–502

Zech DF, Grond S, Lynch J, Hertel D, Lehmann KA (1995) Validation of World Health Organi- zation   Guidelines   for   cancer   pain   relief:   a   10-year   prospective   study.   Pain

63:65–76

Zhang P, Johnson PS, Zöllner C, Wang W, Wang Z, Montes AE, Seidleck BK, Blaschak CJ, Surratt CK (1999) Mutation of human mu opioid receptor extracellular “disulfide cys- teine” residues alters ligand binding but does not prevent receptor targeting to the cell plasma membrane. Brain Res Mol Brain Res 72:195–204

Zöllner C, Shaqura MA, Bopaiah CP, Mousa S, Stein C, Schäfer M (2003) Painful inflammation- induced  increase in mu-opioid  receptor  binding  and G-protein  coupling in primary afferent neurons. Mol Pharmacol 64:202–210

Random Posts

Comments are closed.